ClinicalTrials.gg
Active, not recruitingNCT05729568Updated Apr 27, 2026Results posted

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

A Phase 2 interventional study of Teropavimab and Zinlirvimab in HIV-1 Infection, sponsored by Gilead Sciences. Active, not recruiting at 34 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection.

The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN, TAB and ZAB, versus continuing on baseline oral antiretroviral therapy (ART) as determined by the proportion of participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) ≥ 50 copies/mL at Week 26.

Read the detailed description

Participants will be randomized in Treatment Groups 1 and 2 to receive LEN, TAB, and ZAB, with differing doses of TAB and ZAB between the 2 groups and in Treatment Group 3 to continue their baseline oral ART for 52 weeks. Eligible participants in Treatment Groups 1 through 3 will have the option of participating in the study extension phase to receive LEN, TAB and ZAB after completing study follow-up through Week 52.

Treatment Group 2 was removed prior to dosing of all groups during Protocol Amendment 2.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • On stable oral antiretroviral therapy (ART) consisting of no more than 2 drug classes (with the exception of pharmacologic boosters cobicistat or ritonavir) for ≥ 1 year prior to screening visit 2. A change in ART regimen ≥ 28 days prior to screening visit 2 for reasons other than virologic failure (VF) (eg, tolerability, simplification, drug-drug interaction profile) is allowed.
  • No documented historical resistance to the current ART regimen with the exception of isolated nucleoside reverse transcriptase inhibitor mutations including M184V or ≤ 2 thymidine analog mutations (TAMs: M41L, D67N, K70R, L210W, T215Y, and/or K219Q).
  • Plasma -1 (HIV-1) ribonucleic acid (RNA) \< 50 copies/mL at screening visit 2.
  • Documented plasma HIV-1 RNA \< 50 copies/mL for ≥ 12 months preceding screening visit 2 (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). Virologic elevations of ≥ 50 copies/mL (transient detectable viremia or "blips") prior to screening are acceptable.
  • Proviral phenotypic sensitivity to both teropavimab and zinlirvimab by the PhenoSense Assay (Monogram Biosciences).
  • Screening clusters of differentiation 4 (CD4)+ T-cell count ≥ 200 cells/μL at screening visit 2.

Key Exclusion Criteria:

  • Comorbid condition requiring ongoing .
  • virus (HCV) antibody positive and HCV RNA detectable.
  • Evidence of current virus (HBV) infection regardless of HBV surface antigen status, at the screening visit 2.
  • History of opportunistic infection or illness indicative of Stage 3 HIV disease.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Randomized Phase Treatment Group 1: LEN + TAB + ZAB

    Participants will receive loading dose of lenacapavir (LEN) 600 mg tablets, orally, on Day 1 and Day 2. They will receive LEN 927 mg subcutaneous (SC) injection along with teropavimab (TAB) 2550 mg intravenous (IV) infusion and zinlirvimab (ZAB) 2550 mg IV infusion on Day 1 and every 26 weeks up to Week 52 in the Randomized Phase. At Week 52, participants in this group with HIV-1 RNA \< 50 copies/mL will be given the option to participate in the study extension phase. In the study extension phase, participants will continue to receive their randomized study drugs every 26 weeks.

    Drug: Teropavimab · Drug: Zinlirvimab · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

  • Experimental
    Randomized Phase Treatment Group 3: SBR

    Participants in Stay on Baseline Regimen (SBR) group will continue their baseline oral antiretroviral therapy (ART) up to Week 52. Antiretroviral therapy will include drugs like bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide, administered as per standard of care. At Week 52, participants in this group with HIV-1 RNA \< 50 copies/mL and in the absence of confirmed virologic rebound throughout the Randomized Phase of the study will switch from oral ART to LEN, TAB and ZAB, every 26 weeks. The participants will switch to receive LEN, TAB, and ZAB every 26 weeks beginning at Week 52.

    Drug: Antiretroviral Therapy

  • Experimental
    Extension Phase: Treatment Group 1: LEN + TAB + ZAB

    At Week 52, participants in this group with HIV-1 RNA \< 50 copies/mL will be given the option to participate in the study extension phase. In the study extension phase, participants will receive LEN 927 mg SC, TAB 2550 mg IV infusion and ZAB 2550 mg IV infusion.

    Drug: Teropavimab · Drug: Zinlirvimab · Drug: Lenacapavir Injection

  • Experimental
    Extension Phase Treatment Group 3: SBR

    At Week 52, participants in this group will be given the option to participate in the Extension Phase to switch from oral ART to LEN 927 mg SC, TAB 2550 mg IV infusion and ZAB 2550 mg IV infusion, every 26 weeks at the dose specified for Treatment Group 1.

    Drug: Teropavimab · Drug: Zinlirvimab · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

Interventions

  • Administered intravenously

    Also known as: GS-5423, 3BNC117-LS

  • Administered intravenously

    Also known as: GS-2872, 10-1074-LS

  • Administered orally

    Also known as: GS-6207

  • Administered subcutaneously

    Also known as: GS-6207, Sunlenca®

  • DrugAntiretroviral Therapy

    Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm

    Percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 was analyzed using US FDA-defined snapshot algorithm, which defines a participant's virologic outcome and included participants a) who had last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window; or b) who did not have on-treatment HIV-1 RNA data in the Week 26 analysis window and i) discontinued study drug prior to or in the Week 26 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 26 analysis window due to adverse event (AE) or death and had last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Clopper-Pearson exact method was used to calculate the 95% confidence interval (CI) for the outcome measure of each treatment. Percentages were rounded off.

    Time frame: Week 26

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm

    Percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52 was analyzed using US FDA-defined snapshot algorithm, which defines a participant's virologic outcome and included participants a) who had last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 52 analysis window; or b) who did not have on-treatment HIV-1 RNA data in the Week 52 analysis window and i) discontinued study drug prior to or in the Week 52 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 52 analysis window due to adverse event (AE) or death and had last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 52 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Clopper-Pearson exact method was used to calculate the 95% confidence interval (CI) for the outcome measure of each treatment. Percentages were rounded off.

    Time frame: Week 52

  2. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm

    Percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 26 was analyzed using the US FDA-defined snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 26 analysis window. The Clopper-Pearson exact method was used to calculate the 95% CI for the outcome measure of each treatment. Percentages were rounded off.

    Time frame: Week 26

  3. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm

    Percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 52 was analyzed using the US FDA-defined snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 52 analysis window. The Clopper-Pearson exact method was used to calculate the 95% CI for the outcome measure of each treatment. Percentages were rounded off.

    Time frame: Week 52

  4. Change From Baseline in Clusters of Differentiation 4 (CD4) + T-cell Counts at Week 26

    Time frame: Baseline, Week 26

  5. Change From Baseline in CD4+ T-cell Counts at Week 52

    Time frame: Baseline, Week 52

  6. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 6 years

  7. Trough Concentration at Week 26 Predose for TAB and ZAB

    Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.

    Time frame: Week 26 predose

  8. Trough Concentration at Week 26 Predose for LEN

    Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.

    Time frame: Week 26 predose

  9. Trough Concentration at Week 52 Predose for TAB and ZAB

    Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.

    Time frame: Week 52 predose

  10. Trough Concentration at Week 52 Predose for LEN

    Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.

    Time frame: Week 52 predose

  11. Pharmacokinetic (PK) Parameter: AUC0-tau for TAB and ZAB

    AUC0-tau is defined as the partial area under the concentration versus time curve from time "0" to time "t".

    Time frame: Up to approximately 6 years

  12. PK Parameter: t1/2 for TAB and ZAB

    t1/2 is defined as the terminal elimination half-life.

    Time frame: Up to approximately 6 years

  13. PK Parameter: Cmax for TAB and ZAB

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Up to approximately 6 years

  14. PK Parameter: Cmax for LEN

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Up to approximately 6 years

  15. PK Parameter: Tmax for TAB, ZAB, and LEN

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Up to approximately 6 years

  16. Percentage of Participants With Treatment-emergent Anti-TAB and Anti-ZAB Antibodies

    Anti-TAB and anti-ZAB antibodies incidence referred to the percentage of participants who have treatment-emergent anti-TAB and anti-ZAB antibodies among all participants evaluable for anti-drug antibody (ADA) incidence.

    Time frame: Up to approximately 6 years

07

Results

Posted Jul 15, 2025

Participant flow

241 participants were screened. The study planned to enroll participants in Treatment Groups 1, 2 and 3. However, per review of the programmatic data overall and from study GS-US-536-5816 (NCT04811040), Treatment Group 2 was removed prior to dosing of all groups in the study and did not enroll any participants. Therefore, data is reported only for Treatment Groups 1 and 3.

Randomized Phase
Participant flow — Randomized Phase
MilestoneRandomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRExtension Phase: Treatment Group 1: LEN + TAB + ZABExtension Phase Treatment Group 3: SBR
Started562700
Completed502400
Not completed6300
Withdrew: Still on study2100
Withdrew: Randomized but never treated3000
Withdrew: Adverse event0100
Withdrew: Investigator's discretion1000
Withdrew: Withdrew consent0100
Extension Phase
Participant flow — Extension Phase
MilestoneRandomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRExtension Phase: Treatment Group 1: LEN + TAB + ZABExtension Phase Treatment Group 3: SBR
Started004724
Completed0000
Not completed004724
Withdrew: Still on study004724

Outcome measures

PrimaryPercentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm

Percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 was analyzed using US FDA-defined snapshot algorithm, which defines a participant's virologic outcome and included participants a) who had last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window; or b) who did not have on-treatment HIV-1 RNA data in the Week 26 analysis window and i) discontinued study drug prior to or in the Week 26 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 26 analysis window due to adverse event (AE) or death and had last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Clopper-Pearson exact method was used to calculate the 95% confidence interval (CI) for the outcome measure of each treatment. Percentages were rounded off.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm
percentage of participantsRandomized Phase Treatment Group 1: LEN + TAB+ ZABRandomized Phase Treatment Group 3: SBR
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm1.9 (0.0 to 10.1)0.0 (0.0 to 12.8)
Statistical analysis
  • Randomized Phase Treatment Group 1: LEN + TAB+ ZAB · Fisher Exact · p = 1.0000 · Difference in percentages: 1.9 · 95% CI -11.2 to 10.6Difference in the percentage of participants between treatments and the associated 2-sided 95% CI were constructed based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm

Percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52 was analyzed using US FDA-defined snapshot algorithm, which defines a participant's virologic outcome and included participants a) who had last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 52 analysis window; or b) who did not have on-treatment HIV-1 RNA data in the Week 52 analysis window and i) discontinued study drug prior to or in the Week 52 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 52 analysis window due to adverse event (AE) or death and had last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 52 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Clopper-Pearson exact method was used to calculate the 95% confidence interval (CI) for the outcome measure of each treatment. Percentages were rounded off.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsRandomized Phase Treatment Group 1: LEN + TAB+ ZABRandomized Phase Treatment Group 3: SBR
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm5.7 (1.2 to 15.7)0.0 (0.0 to 12.8)
Statistical analysis
  • Randomized Phase Treatment Group 1: LEN + TAB+ ZAB vs Randomized Phase Treatment Group 3: SBR · Fisher Exact · p = 0.5472 · Difference in percentages: 5.7 · 95% CI -8.0 to 15.8Difference in the percentage of participants between treatments and the associated 2-sided 95% CI were constructed based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm

Percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 26 was analyzed using the US FDA-defined snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 26 analysis window. The Clopper-Pearson exact method was used to calculate the 95% CI for the outcome measure of each treatment. Percentages were rounded off.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsRandomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBR
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm96.2 (87.0 to 99.5)96.3 (81.0 to 99.9)
Statistical analysis
  • Randomized Phase Treatment Group 1: LEN + TAB + ZAB vs Randomized Phase Treatment Group 3: SBR · Fisher Exact · p = 1.0000 · Difference in percentages: -0.1 · 95% CI -10.5 to 15.7Difference in the percentage of participants between treatments and the associated 2-sided 95% CI were constructed based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm

Percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 52 was analyzed using the US FDA-defined snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 52 analysis window. The Clopper-Pearson exact method was used to calculate the 95% CI for the outcome measure of each treatment. Percentages were rounded off.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsRandomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBR
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm88.7 (77.0 to 95.7)92.6 (75.7 to 99.1)
Statistical analysis
  • Randomized Phase Treatment Group 1: LEN + TAB + ZAB vs Randomized Phase Treatment Group 3: SBR · Fisher Exact · p = 0.7104 · Difference in percentages: -3.9 · 95% CI -17.5 to 14.1Difference in the percentage of participants between treatments and the associated 2-sided 95% CI were constructed based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryChange From Baseline in Clusters of Differentiation 4 (CD4) + T-cell Counts at Week 26
Time frame:
Baseline, Week 26
Reported as:
Mean · cells/µL
Change From Baseline in Clusters of Differentiation 4 (CD4) + T-cell Counts at Week 26
cells/µLRandomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBR
Change From Baseline in Clusters of Differentiation 4 (CD4) + T-cell Counts at Week 2623 ± 143.474 ± 202.6
Statistical analysis
  • Randomized Phase Treatment Group 1: LEN + TAB + ZAB vs Randomized Phase Treatment Group 3: SBR · ANCOVA · p = 0.1436 · Difference in least-squares means: -56 · 95% CI -132 to 20Difference in least-squares means, and its 95% CI were from ANCOVA model of change from baseline CD4 cell count with treatment as fixed effect and baseline CD4 cell count as a covariate.
SecondaryChange From Baseline in CD4+ T-cell Counts at Week 52
Time frame:
Baseline, Week 52
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ T-cell Counts at Week 52
cells/μLRandomized Phase Treatment Group 1: LEN + TAB+ ZABRandomized Phase Treatment Group 3: SBR
Change From Baseline in CD4+ T-cell Counts at Week 5210 ± 207.853 ± 123.6
Statistical analysis
  • Randomized Phase Treatment Group 1: LEN + TAB+ ZAB vs Randomized Phase Treatment Group 3: SBR · ANCOVA · p = 0.2390 · Difference in least-squares means: -51 · 95% CI -137 to 35Difference in least-squares means, and its 95% CI were from ANCOVA model of change from baseline CD4 cell count with treatment as fixed effect and baseline CD4 cell count as a covariate.
SecondaryPercentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryTrough Concentration at Week 26 Predose for TAB and ZAB

Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.

Time frame:
Week 26 predose
Reported as:
Mean · µg/mL
Trough Concentration at Week 26 Predose for TAB and ZAB
µg/mLRandomized Phase Treatment Group 1: LEN + TAB + ZAB
TAB41.8 ± 22.7
ZAB72.0 ± 39.2
SecondaryTrough Concentration at Week 26 Predose for LEN

Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.

Time frame:
Week 26 predose
Reported as:
Mean · ng/mL
Trough Concentration at Week 26 Predose for LEN
ng/mLRandomized Phase Treatment Group 1: LEN + TAB+ ZAB
Trough Concentration at Week 26 Predose for LEN20.2 ± 10.6
SecondaryTrough Concentration at Week 52 Predose for TAB and ZAB

Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.

Time frame:
Week 52 predose
Reported as:
Mean · ug/mL
Trough Concentration at Week 52 Predose for TAB and ZAB
ug/mLRandomized Phase Treatment Group 1: LEN + TAB+ ZAB
TAB43.1 ± 17.0
ZAB56.6 ± 26.8
SecondaryTrough Concentration at Week 52 Predose for LEN

Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.

Time frame:
Week 52 predose
Reported as:
Mean · ng/mL
Trough Concentration at Week 52 Predose for LEN
ng/mLRandomized Phase Treatment Group 1: LEN + TAB+ ZAB
Trough Concentration at Week 52 Predose for LEN25.8 ± 14.2
SecondaryPharmacokinetic (PK) Parameter: AUC0-tau for TAB and ZAB

AUC0-tau is defined as the partial area under the concentration versus time curve from time "0" to time "t".

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPK Parameter: t1/2 for TAB and ZAB

t1/2 is defined as the terminal elimination half-life.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPK Parameter: Cmax for TAB and ZAB

Cmax is defined as the maximum observed concentration of drug.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPK Parameter: Cmax for LEN

Cmax is defined as the maximum observed concentration of drug.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPK Parameter: Tmax for TAB, ZAB, and LEN

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Treatment-emergent Anti-TAB and Anti-ZAB Antibodies

Anti-TAB and anti-ZAB antibodies incidence referred to the percentage of participants who have treatment-emergent anti-TAB and anti-ZAB antibodies among all participants evaluable for anti-drug antibody (ADA) incidence.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

Adverse events

Collected over All-cause Mortality and Adverse events: Up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Phase Treatment Group 1: LEN + TAB + ZAB0/56 (0%)1/53 (1.9%)43/53 (81.1%)
Randomized Phase Treatment Group 3: SBR0/27 (0%)1/27 (3.7%)10/27 (37%)
Most frequent serious events
Most frequent serious events
EventRandomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBR
Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/531/27
Perineal abscessInfections and infestations1/530/27
Scrotal abscessInfections and infestations1/530/27
Most frequent other events
Showing 10 of 16
Most frequent other events
EventRandomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBR
Injection site noduleGeneral disorders25/530/27
Injection site painGeneral disorders12/530/27
Injection site erythemaGeneral disorders11/530/27
DiarrhoeaGastrointestinal disorders7/531/27
Injection site indurationGeneral disorders7/530/27
Upper respiratory tract infectionInfections and infestations5/530/27
Covid-19Infections and infestations3/532/27
ParonychiaInfections and infestations0/532/27
Erectile dysfunctionReproductive system and breast disorders0/532/27
ConstipationGastrointestinal disorders3/530/27

Baseline characteristics

The Safety Analysis Set included all participants who were randomized and received at least 1 dose of study drug (ie, study treatment, including LEN, TAB, ZAB, or continued with their baseline ART regimen).

Age, Categorical
Age, Categorical(Participants)Randomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRTotal
<=18 years000
Between 18 and 65 years522678
>=65 years112
Age, Continuous
Age, Continuous(years)Randomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRTotal
Mean44 ± 13.753 ± 9.647 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRTotal
Female8412
Male452368
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Randomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRTotal
Hispanic or Latino13720
Not Hispanic or Latino402060
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Randomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American21829
White281644
More than one race325
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Randomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRTotal
United States481967
Australia268
Puerto Rico213
Canada112
Clusters of Differentiation 4 (CD4)+ T-cell Counts
Clusters of Differentiation 4 (CD4)+ T-cell Counts(cells/µL)Randomized Phase Treatment Group 1: LEN + TAB + ZABRandomized Phase Treatment Group 3: SBRTotal
Mean740 ± 239.3764 ± 264.9748 ± 246.8
08

Study locations

34 sites
09

References and documents

Publications

  • Mponponsuo K, McMahon JH, Gorgos L, Morales-Ramirez J, Workowski K, Brunetta J, Ogbuagu O, Collins SE, VanderVeen LA, Huang H, Baeten JM, Eron JJ. Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome [Oral 07]. Conference on Retroviruses and Opportunistic Infections (CROI); 2025 9-12 March, San Francisco, CA.
  • Ogbuagu O, Gaur A, McMahon JH, Gorgos L, Morales-Ramirez JO, Workowski K, Brunetta J, Mponponsuo K, Collins SE, VanderVeen LA, Zhang N, Huang H, Baeten JM, Eron J. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. Lancet Microbe. 2026 Mar;7(3):101283. doi: 10.1016/j.lanmic.2025.101283. Epub 2026 Feb 17. PubMed 41720146 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jul 2024, 13 months.

Results were first posted in Jul 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2023
First posted
Feb 15, 2023
StartActual
May 15, 2023
Primary completionActual
Jul 2, 2024
CompletionEst.
Dec 2030
Results first posted
Jul 15, 2025
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05729568
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 15, 2023
Start date
May 15, 2023
Primary completion
Jul 2, 2024
Completion
Dec 2030 (estimated)
Results posted
Jul 15, 2025
Last update
Apr 27, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Teropavimab · Zinlirvimab

Start the discussion